TRANSACTION GRANTED EARLY TERMINATION—Continued

ET date	Trans num	ET req status	Party name
		G	Thermoset Plastics, Inc.
	19984667	G	Jones Apparel Group, Inc.
		G	Eric A. Rothfeld.
		G	Sun Apparel, Inc.
	19984668	G	Eric A. Rothfeld.
		G	Jones Apparel Group, Inc.
		G	Jones Apparel Group, Inc.
	19984669	G	Carey International, Inc.
		G	Geroge Jacobs.
		G	American Limousine Partners Inc.
		G	Airport Limousine Repair Service, Inc.
	19984690	G	American Tower Corporation.
		G	Richard H. Stewart.
		G	Wauka Communications, Inc.
		G	Grid Site Services, Inc.
	19984691	G	Mind Spring Enterprises, Inc.
		G	American Online, Inc.
		G	Spry, Inc.
	19984701	G	Journal Communications, Inc.
		G	Great Empire Broadcasting, Inc.
		G	Great Empire Broadcasting, Inc.
	19984708	G	Associated Grocers Incorporated.
		G	Fleming Companies, Inc.
		G	Fleming Companies, Inc.
	19984717	G	Morgan Stanley Dean Witter & Co.
		G	Toy Biz, Inc.
		G	Toy Biz, Inc.
	19984716	G	Triton PCS Holdings, Inc.
		G	AT&T Corp.
		G	AT&T Wireless Services, Inc.
	19984719	G	Citizens Utilities Company.
		G	Rhinelander Telecommunications, Inc.
		G	Rhinelander Telecommunications, Inc.
	19984747	G	General Electric Company.
		G	Pitney Bowes, Inc.
		G	Colonial Pacific Leasing Corporation.
	19984762	G	MBNA Corporation.
		G	The Royal Bank of Scotland Group plc.
		G	Citizens Bank New Hampshire.
		G	Citizens Bank of Rhode Island.
	19984768	G	Pittway Corporation.
		G	Glenn Fischer.
		G	KingAlarm Distributors, Inc.

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202 326–3100.

By Director of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 98–27677 Filed 10–14–98; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Government-Owned Trademark; Availability for Licensing

AGENCY: Centers for Disease Control and Prevention, Office of Technology Transfer, Department of Health and Human Services.

ACTION: Notice: The NIOSHTIC® Trademark named in this notice is owned by the United States Government and is available for licensing in the United States (U.S.) in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development.

SUMMARY: In the last 25 years, the National Institute for Occupational Safety and Health (NIOSH) has developed the world's largest and most comprehensive bibliographic database of occupational safety and health literature (NIOSHTIC® Database). The database is a mature product that is well respected in the field of occupational health and safety and has proven commercial viability. NIOSH is now seeking offers from organizations interested in assuming control and responsibility for the future development, maintenance and marketing of the NIOSHTIC® Database through a trademark licensing agreement.

ADDRESSES: Licensing proposals can be sent to Thomas E. O'Toole, M.P.H., Deputy Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Mailstop E–67, 1600 Clifton Road, Atlanta, Georgia 30333,

telephone (404) 639–6270; facsimile (404) 639–6266.

A. CDC, NIOSH Is Offering

1. Exclusive use of the NIOSHTIC® Database name in relation to the production of the database: The Licensee will have unlimited use of the NIOSHTIC® Trademark for product identification and promotion.

2. Control of the current NIOSHTIC® Database master file: NIOSH will provide the Licensee with a copy of the NIOSHTIC® Database master file as it currently exists. The Licensee may reformat the data, and add or delete fields, provided that the integrity of the file is maintained or enhanced.

3. The authority and responsibility to the licensee to negotiate future agreements with all vendors, and entitlement to collect fees to maintain the database: Licensee will have the option to use existing vendor agreements until they expire, or to terminate (i.e., after a 90-day notice) existing agreements and establish new agreements.

4. An electronic copy of all NIOSH materials generated for the NIOSHTIC–2 database: NIOSH will provide an electronic copy of all citations created for the NIOSHTIC–2 database. These data will be provided in the NIOSHTIC–2 format which is considerably different from the current NIOSHTIC® Database format. The Licensee will be responsible for reformatting the material for inclusion in NIOSHTIC® Database if desired. NIOSHTIC–2 citations will consist of a wide variety of publication types including NIOSH published documents, unpublished NIOSH reports, journal articles, book chapters, etc. Only research reports conducted or funded by NIOSH will be included in NIOSHTIC–2. We anticipate that approximately 600 citations will be added to NIOSHTIC–2 annually.

5. NIOSH staff to provide counsel to Licensee: As modifications of the scope of the NIOSHTIC® Database are considered, NIOSH will provide historical perspective of the interpretations of the current Document Selection Criteria and the Core Journal List as well as all other aspects of the project.

B. NIOSH Expects the Licensee to

1. Maintain NIOSHTIC® Database as an active, viable occupational safety and health database: The Licensee must not radically alter the scope of the NIOSHTIC® Database, but modification of the current Document Selection Criteria and Core Journal List is acceptable and expected as the needs of the users dictate.

2. Market NIOSHTIC® Database so that it is available to the international occupational safety and health community: The Licensee must make NIOSHTIC® Database available worldwide in a variety of forms such as on-line, CD–ROM, and/or the Internet using the NIOSHTIC® Trademark.

3. Provide multiple point, free, and unlimited access to NIOSH employees for all products resulting from this licensing agreement: NIOSH research and information staff must have access to what will remain the world's largest and most comprehensive bibliographic database of occupational safety and health information.

4. Allow NIOSH representation on any editorial or policy board for the database: A NIOSH representation should serve on any editorial or policy board established for the NIOSHTIC® Database to ensure that the Institute's interests are considered.

5. Provide sufficient royalties to cover NIOSH's expenses for meeting travel, orientation to the product, consultation on policy issues or oversight activity as desired by either party: NIOSH believes that the overwhelming majority of revenue generated should be reinvested in the development and maintenance of the NIOSHTIC® Database and related projects.

Dated: October 8, 1998.

Thena M. Durham,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention.

[FR Doc. 98–27641 Filed 10–14–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97E–0270]

Determination of Regulatory Review Period for Purposes of Patent Extension; Aldara™ (4,689,338)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for Aldara™ (4,689,338) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–6620.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product Aldara™ (4,689,338) (imiquimod). Aldara™ (4,689,338) is indicated for the treatment of external genital and perianal warts/condyloma acuminata in adults. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for Aldara™ (4,689,338) (U.S. Patent No. 4,689,338) from Riker Laboratories, Inc., and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated July 22, 1997, FDA advised the Patent